Atorvastatin Combining with Probucol: A New Way to Reduce Serum Uric Acid Level during Perioperative Period of Interventional Procedure

Author:

Li Hong12,Li Ximing3,Ma Hongjun4,Wang Yiran3,Fu Naikuan3,Jin Dongxia3,Cong Hongliang3

Affiliation:

1. Graduate School, Tianjin Medical University, Tianjin 300051, China

2. Department of Geriatrics, The First Hospital of Qinhuangdao, Qinhuangdao 066000, China

3. Department of Cardiology, Tianjin Chest Hospital, Tianjin Medical University, Xi’an Road No. 93, Heping District, Tianjin, 300051, China

4. Cardiology Department, Dagang Oil Field General Hospital, Tianjin Medical University, Tianjin 300051, China

Abstract

Uric acid has ever been considered as one of contrast induced acute kidney injury’s risk factors. Atorvastatin and probucol can both improve contrast induced acute kidney injury separately. This prospective study is to assess their effect on reducing serum uric acid level and contrast induced acute kidney injury during perioperative period of interventional procedure. On the basis of different doses of atorvastatin and probucol, 208 cases admitted for coronary angiography or percutaneous coronary intervention were randomly classified into standard combined group (S-C group), intensive combined group (I-C group), and intensive atorvastatin group (I-A group). Patients’ blood urea nitrogen, serum creatinine, and serum uric acid were measured and estimated glomerular filtration rate was evaluated 24 hours before and after the procedure. After procedure, blood urea nitrogen in all the three groups decreased; Scr of S-C group and I-A group increased significantly, while estimated glomerular filtration decreased in the S-C group (P<0.05); serum uric acid in S-C group and I-C group decreased significantly (P<0.05). Combination treatment of atorvastatin and probucol before intervention could reduce perioperative serum uric acid level; meanwhile, the intensive combined treatment can improve the contrast induced acute kidney injury. The result was the same for hypertensive patients.

Funder

Tianjin Science and Technology Support Plan

Publisher

Hindawi Limited

Subject

General Environmental Science,General Biochemistry, Genetics and Molecular Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3